Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Managing anti-thrombotic therapy in patients on long-term anticoagulation undergoing coronary intervention presents significant clinical challenges.
• Optimizing treatment strategies is crucial to balance the risk of thrombosis and bleeding.

Purpose of the Study:

• To compare the efficacy and safety of dual therapy versus triple therapy in patients on long-term anticoagulation after percutaneous coronary intervention (PCI).
• To determine the optimal anti-thrombotic regimen to minimize bleeding while maintaining cardiovascular protection.

Main Methods:

• A meta-analysis was conducted, including observational studies and randomized controlled trials.
• The analysis compared dual therapy (P2Y12 inhibitor and anticoagulant) with triple therapy (dual antiplatelet therapy and anticoagulant).
• Major bleeding was the primary outcome of interest.

Main Results:

• The meta-analysis included 6654 patients across 3 observational studies and 3 randomized controlled trials.
• Dual therapy was associated with significantly lower rates of major bleeding (2.2% vs 5.2%) compared to triple therapy.
• No significant differences were observed between the groups for major adverse cardiac events, all-cause mortality, myocardial infarction, target vessel revascularization, thromboembolic events, or stent thrombosis.

Conclusions:

• A dual therapy strategy (P2Y12 inhibitor plus anticoagulant) is beneficial for patients undergoing PCI who require long-term anticoagulation.
• This approach reduces major bleeding without compromising cardiovascular outcomes like major adverse cardiac events or mortality.
• Dual therapy offers a safer alternative to triple therapy in this patient population.